Navigation Links
George Soros to Boost Civil Society Response in Flood Affected Areas of Pakistan
Date:8/17/2010

NEW YORK, Aug. 17 /PRNewswire-USNewswire/ -- In response to unprecedented devastation and human suffering caused by the flooding in Pakistan, the Open Society Foundations today announced it would give an additional $5 million to its foundation there to respond to the humanitarian crisis.

"We need everyone to pitch in to the extent they can," said Absar Alam, country head of the Open Society Foundation in Pakistan – FOSI-Pakistan. "While the government and people of Pakistan are struggling to organize and manage relief efforts, the disaster is much bigger than what they alone can handle."

In the immediate future, the $5 million will support emergency provisions like food, clean water, tents and shelter, medicine and medical supplies to people in flood-hit areas. The foundation also hopes to support reconstruction projects like restoring roads and bridges, repairing the electricity infrastructure, and rebuilding homes.

George Soros, chairman of the Open Society Foundations, earlier this month gave an initial relief gift of $50,000 to BRAC Pakistan, an anti-poverty group, to provide emergency relief services to people in the flooded regions. Given the unrelenting severity of the disaster, Mr. Soros, on the request of Pakistan office, decided to follow up with additional support of $5 million.

Since 2004, the Open Society Foundations have spent several million dollars to bolster civil society in Pakistan by supporting education, media, and the reconstruction campaign after the 2005 earthquake. A call for proposals for civil society organizations will be launched by the Open Society Foundation in Pakistan – FOSI-Pakistan.

Active in more than 70 countries, the Open Society Foundations work to build vibrant and tolerant democracies whose governments are accountable to their citizens. Working with local communities, the Open Society Foundations support justice and human rights, freedom of expression, and access to publi
'/>"/>

SOURCE Open Society Foundations
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
2. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
3. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
4. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
5. New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production
6. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
7. Pregnant Women Need Omega-3 to Boost Infant Development
8. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus
11. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 ResearchMoz presents this ...  Laparoscopes Market Outlook to 2020. New report, "United States ... on the United States Laparoscopes market . The ... (in units) and average prices (in US dollars) within ... Flexible Tip Video Laparoscopes), Robotic Surgical Systems and Rigid ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new market ... Baby Food Eastern Europe 2014 ... 2014" is a new report by ERC that analyzes ... Eastern Europe , key segments, features & developments, ... examines trends which are currently affecting the industry. Furthermore, ...
(Date:8/27/2014)... 27, 2014 Sihuan Pharmaceutical Holdings Group ... a leading pharmaceutical company with the largest cardio-cerebral ... prescription drug market, today announced the ... subsidiaries (collectively the "Group") for the six months ... Financial HighlightsFor the Six months ended 30 JuneKey ...
Breaking Medicine Technology:United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... in non-responders to previous interferon-based therapy -, ... non- responders, with less frequent ... Annual Meeting of the American Association for the Study of Liver Diseases ... (AASLD) -, ...
... N.C., Nov. 2 /PRNewswire/,-- Fabre-Kramer Pharmaceuticals Inc. (FKP) ... the U.S. Food and Drug Administration (FDA) has ... application for gepirone extended-,release (ER) tablets, submitted for ... The FDA had previously reviewed Phase I through ...
Cached Medicine Technology:Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder 2
(Date:8/27/2014)... clinical trial participation in the largest ongoing observational study ... not representative of the larger patient base, according to ... Jay Udell. The study authors call into question the ... and suggest the use of broader enrollment criteria and ... know that clinical trials can be tremendously expensive and ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Representatives with ... added Italy to its list of destinations for International ... for Recharge Retreats, explained that the company chose Italy ... destination for yoga teacher trainings since it's an easy ... journey for people traveling from all over Europe, UK, ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Many ... The reality is that depression has a mortality rate ... with bi-polar disorder is slightly less, though it's offset ... roughly 7%. In order to properly treat and ... and bi-polar, medication must be taken as directed. ...
(Date:8/27/2014)... California (PRWEB) August 27, 2014 Beginning in ... Daycare Olympic Games (DOG) as an interactive, fun way ... will be free to all K9 Dog Park Doggy Daycare ... least two days per week. Clients will be able ... daycare webcams. The dogs that compete in D.O.G. will ...
(Date:8/27/2014)... HealthDay Reporter TUESDAY, Aug. 26, 2014 ... for blood transfusions might also protect the brains of premature ... stimulates red blood cell production, appears to prevent brain damage ... Petra Huppi, a professor of pediatrics and newborn medicine at ... of whether EPO protects the brains of these children will ...
Breaking Medicine News(10 mins):Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 3Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 3Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 4Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3
... Medicated heart patients might be in danger, study suggests ... boost blood pressure and heart rate and could pose ... Wayne State University researchers. , They found that drinking ... pressure and heart rate in 15 healthy adults, average ...
... controlled, multi-center trial has found that cardiac resynchronization ... during exercise testing, the trial,s primary endpoint, in ... problems that disrupt the heart,s normal rhythm and ... EKG. , The Resynchronization Therapy in Narrow QRS ...
... Nov. 6 ,PharmAthene, Inc. (Amex: PIP ), ... chemical threats, and Medarex, Inc.,(Nasdaq: MEDX ), ... FY 2008 Department of Defense (DoD) appropriations bill ... reimbursement basis to support,ongoing development of Valortim(TM), a ...
... Neurotech Pharmaceuticals, Inc.,a biotechnology company focused on ... diseases, announced today the completion,of enrollment of ... evaluating,NT-501, the Company,s lead product, for the ... (RP) and the dry form of age-related,macular ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three and ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) Revenues for the third ... comparable period a year ago. The Company,reported a ...
... - Bioniche Life Sciences,Inc. (TSX: BNC), a research-based, ... Executive,Vice-President, Corporate & Strategic Development, will present at ... in New York City,tomorrow. Mr. Groome will present ... Room of the New York Palace Hotel. ...
Cached Medicine News:Health News:Energy Drinks Could Pose Blood Pressure Risks 2Health News:Study puts brakes on extending indications for cardiac resynchronization therapy 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 3Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 4Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 5Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 6Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 7Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 2Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 2Health News:EntreMed Reports Third Quarter 2007 Financial Results 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 4Health News:EntreMed Reports Third Quarter 2007 Financial Results 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: